Cooley, Baker McKenzie Steer Vaccine Deal Worth Up To $1.06B
By Elise Hansen ( October 21, 2019, 2:04 PM EDT) -- GlaxoSmithKline said Monday it will sell its rabies and tick-borne encephalitis vaccines to biotechnology company Bavarian Nordic for up to €955 million ($1.06 billion) in a deal steered by Cooley LLP and Baker & McKenzie LLP....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.